The NHS is facing criticism over the unequal distribution of new weight loss injections, such as Mounjaro, with patients in some areas denied access while others receive the treatment. This inconsistency has sparked concerns over a growing 'postcode lottery' in obesity care.
What’s Happening?
Mounjaro, a promising new drug for weight management, is being prescribed in certain regions but remains unavailable in others. Experts warn that this patchwork rollout is leaving many patients without vital support, despite meeting clinical eligibility criteria.
Why Does It Matter?
Obesity is a major public health crisis in the UK, linked to conditions like diabetes and heart disease. Effective treatments like Mounjaro could help, but inconsistent access undermines efforts to tackle the issue fairly.
What’s Next?
Campaigners are urging NHS leaders to standardise access, ensuring all eligible patients can benefit—regardless of where they live. Without action, health inequalities could widen further.
